Sentynl Therapeutics, a biopharmaceutical company based in the USA and wholly owned by Zydus Lifesciences, has appointed myTomorrows as the global provider for its Managed Access Program (MAP). The transition to myTomorrows’ patient-centric platform reinforces Sentynl’s commitment to expanding access to investigational treatments for people living with rare and ultra-rare diseases such as Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.

Under the new arrangement, myTomorrows, a global health technology company, will help connect patients whose needs are not met by existing standard therapies with pre-approval treatment options. This includes access to clinical trials and expanded access or managed access pathways, with a focus on supporting patients around the world with complex conditions and limited treatment options. The move is expected to broaden the reach of Sentynl’s MAP while maintaining high standards of regulatory compliance and service.

Sentynl’s president and chief executive officer highlighted the company’s mission to ensure that patients with rare diseases have access to potentially life-extending therapies. He emphasised that partnering with myTomorrows, which brings deep expertise and a forward-thinking approach, will enhance the programme’s impact and improve support for patients and physicians navigating access to therapies before formal regulatory approval.

The chief executive officer of myTomorrows said the company is proud to support Sentynl in making treatment options more widely available and reducing barriers related to geography and regulatory differences. With its global access solutions, regulatory know-how and patient-focused services, myTomorrows aims to scale access to Sentynl’s managed access initiatives.

The two organisations also plan to strengthen their collaboration across additional managed access programmes for other rare and ultra-rare diseases. This partnership highlights a shared vision that patients worldwide should be empowered to access innovative therapies they urgently need, irrespective of location or regulatory delays.

myTomorrows has built proprietary technology that searches clinical trial and expanded access registries to efficiently connect patients, physicians, trial sites and biopharmaceutical companies. The platform has supported access for thousands of patients and physicians across multiple countries, offering a route to potentially transformative treatments for conditions lacking approved therapies.